On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell ...

ToolGen files patent infringement lawsuit against Vertex Pharma in UK for genome editing therapy CASGEVY: Seoul, South Korea Tuesday, April 22, 2025, 15:00 Hrs [IST] ToolGen, Inc.

Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...